In a recent transaction, Leonard E. Post (NYSE:POST), a director at CG Oncology, Inc. (NASDAQ:CGON), sold 1,000 shares of the company's common stock. The shares were sold at an average price of $28.84, totaling approximately $28,840. This sale was conducted under a Rule 10b5-1 trading plan, which was adopted by Post on September 6, 2024. The transaction comes as CGON shares have declined about 13% over the past week, with the company currently maintaining a market capitalization of approximately $2 billion.
The Form 4 filing also disclosed that Post exercised stock options to acquire 1,000 shares of common stock at a price of $0.60 per share, amounting to a total value of $600. Following these transactions, Post no longer holds any shares directly from this particular transaction.
CG Oncology, based in Irvine, California, is a life sciences company focused on developing biological products.
In other recent news, CG Oncology has been generating attention due to promising results from its Phase 3 BOND-003 study, which focuses on cretostimogene for treating high-risk non-muscle invasive bladder cancer. The company reported a 74.5% overall complete response rate and a 46% 12-month landmark complete response rate. The study also highlighted the safety and durability of cretostimogene, with 97.3% of patients remaining progression-free at 12 months and 90.0% achieving cystectomy-free survival.
H.C. Wainwright maintained a Buy rating and a $75.00 stock price target for CG Oncology, while UBS initiated coverage with a Buy rating and a $60.00 price target, emphasizing cretostimogene's potential advantages over competitors. Goldman Sachs (NYSE:GS) also reiterated its Buy rating on CG Oncology, maintaining a $52.00 price target, and emphasized the potential of cretostimogene in treating non-muscle invasive bladder cancer.
Roth/MKM issued a Buy rating with a $65.00 price target, citing cretostimogene's potential to capture market share due to its tolerability. The final analysis from CG Oncology's BOND-003 trial is expected by the end of 2024, coinciding with the company's plans for a Biologics License Application submission in 2025. These developments highlight the ongoing interest in CG Oncology's work in the oncology space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.